MaxCyte Inc’s recently made public that its Director Hemrajani Rekha acquired Company’s shares for reported $22378.0 on Jun 25 ’25. In the deal valued at $2.09 per share,10,684 shares were bought.
Then, Soleymannezhad Ali sold 1,211 shares, generating $3,850 in total proceeds. Upon selling the shares at $3.18, the Chief Commercial Officer now owns 59,439 shares.
Before that, Sandoval David I. sold 353 shares. MaxCyte Inc shares valued at $1,122 were divested by the GENERAL COUNSEL at a price of $3.18 per share. As a result of the transaction, Sandoval David I. now holds 64,219 shares, worth roughly $0.14 million.
Craig Hallum initiated its MaxCyte Inc [MXCT] rating to a Buy in a research note published on November 29, 2023; the price target was $7. William Blair began covering MXCT with “an Outperform” recommendation on August 24, 2021. Wedbush started covering the stock on August 24, 2021. It rated MXCT as “an Outperform”.
Price Performance Review of MXCT
On Tuesday, MaxCyte Inc [NASDAQ:MXCT] saw its stock jump 2.30% to $2.22. Over the last five days, the stock has gained 1.83%. MaxCyte Inc shares have fallen nearly -40.96% since the year began. Nevertheless, the stocks have fallen -46.63% over the past one year. While a 52-week high of $5.20 was reached on 01/21/25, a 52-week low of $2.00 was recorded on 06/25/25.
Levels Of Support And Resistance For MXCT Stock
The 24-hour chart illustrates a support level at 2.18, which if violated will result in even more drops to 2.13. On the upside, there is a resistance level at 2.26. A further resistance level may holdings at 2.29.
How much short interest is there in MaxCyte Inc?
A steep rise in short interest was recorded in MaxCyte Inc stocks on 2025-06-13, dropping by -0.27 million shares to a total of 3.56 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 3.83 million shares. There was a decline of -7.47%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 24, 2021 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $18 price target.
